**Author details**

Ana Lilia Pérez-Balbuena1 , David Arturo Ancona-Lezama1 , Lorena Gutiérrez-Sánchez1 and Virginia Vanzzini-Zago2

1 Cornea Service. Asociación para Evitar la Ceguera en México I.A.P. "Hospital. Dr. Luis Sánchez Bulnes". Vicente García Torres,México D.F., México

2 Laboratory of Microbiology. Asociación para Evitar la Ceguera en México I.A.P. "Hospital. Dr. Luis Sánchez Bulnes". Vicente García Torres, México D.F., México

### **References**


[21] Nash KA, Zhang Y, Brown-Elliott BA, et al. Molecular basis of intrinsic macrolide re‐ sistance in clinical isolates of Mycobacterium fortuitum. J AntimicrobChemother. 2005; 55:170-177.

[7] Garg P, Bansal AK, Sharma S, Vemuganti GK. Bilateral infectious keratitis after laser in situ keratomileusis: a case report and review of the literature. Ophthalmology.

[8] Kouyoumdjian GA, Forstot SL, Durairaj VD, Damiano RE. Infectious keratitis after

[9] Maloney RK. Cluster of Mycobacterium chelonae keratitis cases following laser in

[10] Solomon A, Karp CL, Miller D, Dubovy SR, Huang AJ, Culbertson WW. Mycobacte‐ rium interface keratitis after laser in situ keratomileusis. Ophthalmology.

[11] Sossi N, Feldman RM, Feldman ST, Frueh BE, McGuiere G, Davis C. Mycobacterium gordonae keratitis after penetrating keratoplasty Arch. Ophthalmol. 1991:109(8):

[12] Winthrop KL, Steinberg EB, Holmes G, Kainer MA, Werner SB, Winquist A, Vugia DJ. Epidemic and sporadic cases of nontuberculous mycobacterial keratitis associat‐

[13] Pfyffer GE, Palicova F. Mycobacterium: General characteristics, laboratory detection, and staining procedures. In Versalovic J, Carrol KC, Funke G, Jorgensen JH, Landry ML, Warnock DW. Manual of Clinical Microbiology 10th ed. ASM press. Washington

[14] Runyon EH. Identification of mycobacterial pathogens using colony characteristics.

[15] Vincent V, Brown-Elliot BA, Jost KC Jr, et al. Mycobacterium: Phenotypic and Geno‐ typic Identification, in Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH (eds) Manual of Clinical Microbiology. Vol. 1. Washington, DC, ASM Press, 2003, 8th

[16] Broadway DC, Kerr-Muir MG, Eykyn SJ, Pambakian H. Mycobacterium chelonei ker‐ atitis: a case report and review of previously reported cases. Eye 1994; 8: 134-142. [17] Fowler AM, Dutton JJ, Fowler WC, et al. Mycobacterium chelonaecanaliculitis associ‐

[18] Chang WJ, Tse DT, Rosa RH Jr, et al. Periocular atypical mycobacterial infections.

[19] Mauriello JA Jr. Atypical Mycobacterial Study G. Atypical mycobacterial infection of the periocular region after periocular and facial surgery. OphthalPlastReconstr Surg.

[20] Margo CE, Pavan PR. Mycobacterium chelonae conjunctivitis and scleritis following

ated with SmartPlug use. Ophthal Plast ReconstrSurg. 2008;24:241-243.

[see comment]. Ophthalmology. 1999;106:86-90.

vitrectomy. Arch Ophthalmol. 2000;118:1125—1128.

ed with laser in situ keratomileusis. Am J Ophthalmol. 2003;135(2):223-224.

laser refractive surgery. Ophthalmology. 2001 Jul;108(7):1266-1268.

situ keratomileusis. Am J Ophthalmol. 2002:134(2):298-299.

2001;108(1):121-125.

168 Common Eye Infections

2001:108(12):2201-2208.

1064-1065.

DC. 472-502.

ed, pp 560-658.

2003;19:182-188

Am J ClinPathol. 1970;54:578-586.


[50] Pérez-Balbuena AL, Santander-García D, Vanzzini-Zago V. Therapeutic Keratoplasty for Microbial Keratitis. In: MoscaL. Keratoplasties. Surgical Techinques and Compli‐ cations. Rijeka: InTech; 2011.

[37] Knickelbein JE, Hendricks RL, Charukamnoetkanok P. Management of herpes sim‐ plex virus stromal keratitis: An evidence-based review. SurvOphthalmol.

[38] Schonherr U, Naumann GO, Lang GK, et al. Sclerokeratitis caused by Mycobacteri‐

[39] Donnenfeld ED, Kim TK, Holland EJ Azar DT, Palmon FR, Rubenstein JB, Daya S, Yoo SH. American Society of Cataract and Refractive Sugery Cornea Clinical Com‐ mittee. ASCRS White Paper. Management of infectious keratitis following laser in

[40] Llovet F, de Rojas V, Interlandi E, Martín C, Cobo-Soriano R, Ortega-Usobiaga J, Ba‐ viera J. Infectiouskeratitia in 204586 LASIK procedures. Ophthalmology

[41] Pérez-Balbuena AL, Vanzzini-Zago V, Garza M, Cuevas-Cancino D. Atypical Myco‐ bacterium Keratitis Associated With Penetrating Keratoplasty: Case Report of Suc‐

[42] Bullington RH Jr, Lanier JD, Font RL. Nontuberculous mycobacteria keratitis; report of two cases and review of the literature. Arch Ophthalmol 1992;110:519-524.

[43] Hu F-R, Luh K-T. Topical ciprofloxacin for treating nontuberculous mycobacterial

[44] Schlech BA, Alfonso E. Overview of the potency of moxifloxacin ophthalmic solution

[45] Hamam RN, Noureddin B, Salti H, et al. Recalcitrant post-LASIK Mycobacterium chelonae keratitis eradicated after the use of fourth-generation fluoroquinolones.

[46] Hyon JY, Joo MJ, Hose S, et al comparative efficacy of topical gatifloxacin with cipro‐ floxacin, amikacin, and clarithromycin in the treatment of experimental Mycobacteri‐

[47] Shih et al have reported full months of therapy even when the appropriate antibiotic, chosen by drug sensitivity test results, is used. (Shih MH, Huang FC. Effects of Pho‐ todynamic Therapy on Rapidly Growing Nontuberculous Mycobacteria Keratitis. In‐

[48] Banoch PR, Hay GJ, McDonellPJ, et al. A rat model of bacterial keratitis :effects of an‐

[49] Leibowitz HM, Kupferman A. Topically administered corticosteroids: effect with an‐

cessful Therapy With Topical Gatifloxacin 0.3%. Cornea 2010;29:468-470.

um marinum. Am J Ophthalmol. 1989;108:607-608

keratitis. Ophthalmology 1998;105:269-272.

Ophthalmology 2006;113:950-954.

vest Ophthalmol Vis Sci. 2011; 52:223-229.

situ keratomileusis. J Cataract Refract Surg 2005;31:2008-2011.

0.5% (VIGAMOX®). SurvOphthalmol 2005;50(suppl):S7-S15.

um chelonae keratitis. Arch Ophthalmol 2004,122:1166-1169.

tibiotics and corticosteroids. Arch Ophthalmol 1980,98:718-20.

tibiotic treated bacterial keratitis. Arch opthalmol 1980, 98: 1287-1290.

2009;54:226-234.

170 Common Eye Infections

2010;117:232-238.
